Payment overview · 2025
General Payments
$1,543.52
62 reported records · 18 companies
Healthcare provider profile · identity verified
Missak Kltchian, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LOS ANGELES, CA · NPI 1255359840
Verified facts
What the public records show
CMS Open Payments records show Missak Kltchian, MD received $1,543.52 in general payments during 2025 across 62 reported records.
ABBVIE INC. accounted for 13.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Gemtesa, Jardiance, Linzess, Mounjaro, Ozempic, Rybelsus, Tresiba, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 514 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Zenpep by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Nexium by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 514 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Tresiba by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulance by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $209.88 | 13.6% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $199.28 | 12.9% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.95 | 11.2% | 7 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $152.16 | 9.9% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $151.10 | 9.8% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $108.63 | 7.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $91.91 | 6.0% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.85 | 5.0% | 3 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.68 | 4.4% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $57.48 | 3.7% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $52.53 | 3.4% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $36.67 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.42 | 2.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.08 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.13 | 1.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $29.79 | 1.9% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.23 | 1.5% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $19.75 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,543.52 | 62 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $199.28 | 7 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $183.27 | 7 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $152.16 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $151.10 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $128.30 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $115.86 | 5 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $113.43 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $108.63 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $108.63 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $91.91 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $77.85 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $67.68 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.48 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.48 | 3 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $57.48 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $57.09 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $52.53 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $36.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $31.42 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.13 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $26.61 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $26.61 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $23.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 142 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 100 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 244 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 514 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 84 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 153 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Tresiba tresiba |
2025 | Tresiba | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
142 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
514 | 62 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
78 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 31 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
514 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
244 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
74 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
153 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 29 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1474 | 169 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1365 | 155 |
| Losartan Potassium | Losartan Potassium | 1266 | 152 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1094 | 162 |
| Gabapentin | Gabapentin | 861 | 92 |
| Metformin Hcl | Metformin Hcl | 852 | 107 |
| Omeprazole | Omeprazole | 839 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 669 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 652 | 87 |
| Dexlansoprazole Dr | Dexlansoprazole | 607 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 603 | 66 |
| Diclofenac Sodium | Diclofenac Sodium | 531 | 105 |
| Linzess | Linaclotide | 514 | 62 |
| Ketoconazole | Ketoconazole | 449 | 79 |
| Furosemide | Furosemide | 442 | 60 |
| Carvedilol | Carvedilol | 409 | 52 |
| Levothyroxine Sodium | Levothyroxine Sodium | 382 | 46 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 369 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 43 |
| Vascepa | Icosapent Ethyl | 332 | 58 |
| Icosapent Ethyl | Icosapent Ethyl | 325 | 60 |
| Celecoxib | Celecoxib | 317 | 37 |
| Allopurinol | Allopurinol | 315 | 34 |
| Glimepiride | Glimepiride | 310 | 36 |
| Meloxicam | Meloxicam | 305 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 273 | 33 |
| Sertraline Hcl | Sertraline Hcl | 271 | 32 |
| Azithromycin | Azithromycin | 251 | 152 |
| Jardiance | Empagliflozin | 244 | 31 |
| Atenolol | Atenolol | 235 | 23 |
| Memantine Hcl | Memantine Hcl | 221 | 29 |
| Single Use Swab | Alcohol Antiseptic Pads | 215 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 214 | 24 |
| Benazepril Hcl | Benazepril Hcl | 212 | 24 |
| Eliquis | Apixaban | 209 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 188 | 27 |
| Clonidine Hcl | Clonidine Hcl | 182 | 26 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 174 | 37 |
| Alprazolam | Alprazolam | 169 | 19 |
| Famotidine | Famotidine | 160 | 23 |
| Meclizine Hcl | Meclizine Hcl | 155 | 30 |
| Ozempic | Semaglutide | 153 | 25 |
| Finasteride | Finasteride | 150 | 20 |
| Levofloxacin | Levofloxacin | 150 | 102 |
| Lidocaine | Lidocaine | 150 | 16 |
| Tramadol Hcl | Tramadol Hcl | 150 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 17 |
| Lisinopril | Lisinopril | 144 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 144 | 18 |
| Creon | Lipase/Protease/Amylase | 142 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 21 |
| Colchicine | Colchicine | 136 | 18 |
| Repatha Sureclick | Evolocumab | 132 | 16 |
| Xarelto | Rivaroxaban | 132 | 14 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 130 | 14 |
| Trazodone Hcl | Trazodone Hcl | 130 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 128 | 40 |
| Nebivolol Hcl | Nebivolol Hcl | 128 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 127 | 15 |
| Baclofen | Baclofen | 125 | 17 |
| Ezetimibe | Ezetimibe | 124 | 18 |
| Ibuprofen | Ibuprofen | 121 | 25 |
| Lansoprazole | Lansoprazole | 117 | 18 |
| Amiodarone Hcl | Amiodarone Hcl | 116 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 113 | 30 |
| Memantine Hcl Er | Memantine Hcl | 112 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 109 | 20 |
| Clonidine | Clonidine | 104 | 12 |
| Gemtesa | Vibegron | 100 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 99 | 12 |
| Procto-Med Hc | Hydrocortisone | 99 | 16 |
| Alendronate Sodium | Alendronate Sodium | 97 | 15 |
| Metformin Er Gastric | Metformin Hcl | 95 | 11 |
| Valsartan | Valsartan | 95 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 89 | 14 |
| Myrbetriq | Mirabegron | 89 | 17 |
| Trulicity | Dulaglutide | 89 | suppressed |
| Januvia | Sitagliptin Phosphate | 88 | 14 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 87 | 30 |
| Mounjaro | Tirzepatide | 84 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 83 | 11 |
| Nitroglycerin | Nitroglycerin | 82 | 13 |
| Fenofibrate | Fenofibrate | 78 | 16 |
| Nexium | Esomeprazole Magnesium | 78 | suppressed |
| Repaglinide | Repaglinide | 78 | suppressed |
| Fluocinonide | Fluocinonide | 77 | 13 |
| Montelukast Sodium | Montelukast Sodium | 75 | 11 |
| Entresto | Sacubitril/Valsartan | 74 | 12 |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 71 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 71 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 70 | 16 |
| Tradjenta | Linagliptin | 69 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 69 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 65 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 65 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 64 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 59 | suppressed |
| Simvastatin | Simvastatin | 59 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 57 | suppressed |
| Nifedipine Er | Nifedipine | 57 | suppressed |
| Clonazepam | Clonazepam | 56 | suppressed |
| Mirtazapine | Mirtazapine | 55 | suppressed |
| Lorazepam | Lorazepam | 54 | suppressed |
| Ssd | Silver Sulfadiazine | 52 | 23 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | suppressed |
| Cyclosporine | Cyclosporine | 49 | suppressed |
| Novolog Flexpen | Insulin Aspart | 48 | 16 |
| Nateglinide | Nateglinide | 47 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 46 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 42 | suppressed |
| Ofloxacin | Ofloxacin | 42 | 25 |
| Primidone | Primidone | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Dutasteride | Dutasteride | 39 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 39 | suppressed |
| Prednisone | Prednisone | 39 | 11 |
| Spironolactone | Spironolactone | 39 | suppressed |
| Trulance | Plecanatide | 39 | suppressed |
| Brilinta | Ticagrelor | 38 | suppressed |
| Dutasteride-Tamsulosin | Dutasteride/Tamsulosin Hcl | 38 | suppressed |
| Hydrocortisone | Hydrocortisone | 38 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 36 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 32 | suppressed |
| Fluvastatin Sodium | Fluvastatin Sodium | 32 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Rybelsus | Semaglutide | 32 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 31 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Febuxostat | Febuxostat | 30 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 30 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 12 |
| Ramipril | Ramipril | 29 | suppressed |
| Aripiprazole | Aripiprazole | 28 | suppressed |
| Multaq | Dronedarone Hcl | 28 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Potassium Chloride | Potassium Chloride | 27 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 27 | 14 |
| Farxiga | Dapagliflozin Propanediol | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Veo Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 25 | suppressed |
| Cefdinir | Cefdinir | 24 | 20 |
| Edarbi | Azilsartan Medoxomil | 24 | suppressed |
| Latuda | Lurasidone Hcl | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Fluocinolone Acetonide | Fluocinolone Acetonide | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Metolazone | Metolazone | 23 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 22 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Ciclopirox | Ciclopirox | 20 | suppressed |
| Dexilant | Dexlansoprazole | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 18 | suppressed |
| Praluent Pen | Alirocumab | 18 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 18 | 14 |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Tresiba | Insulin Degludec | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Novolog | Insulin Aspart | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Briviact | Brivaracetam | 14 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 14 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Diclofenac Epolamine | Diclofenac Epolamine | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Exforge | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Rhopressa | Netarsudil Mesylate | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Apidra Solostar | Insulin Glulisine | 11 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 11 | suppressed |
| Dofetilide | Dofetilide | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,543.52 · 62 records | ABBVIE INC. | ACCRUFER, AIRSUPRA, BREZTRI, CREON, Dexcom G6 Transmitter, GEMTESA, IBSRELA, JARDIANCE, LEQVIO, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, Tresiba, UBRELVY, VOQUEZNA, Veozah, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 22 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error